• Immix Biopharma will present interim NXC-201 trial results at the American Society of Hematology meeting on December 14, 2026.
• The 45-patient NEXICART-2 study evaluates safety and efficacy in the first U.S. CAR-T trial for relapsed or refractory AL amyloidosis.
• The results were selected for an oral presentation scheduled for 11:15 a.m. Central Time in New Orleans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040915PRIMZONEFULLFEED9869832) on November 04, 2026, and is solely responsible for the information contained therein.